New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 11, 2012
11:25 EDTDKAM, DKAM, LTBR, LTBR, NBS, NBS, LQMT, LQMT, NVTL, NVTL, ASUR, ASUR, GALE, GALE, LLTC, LLTC, AEMD, AEMD, TAS, TAS, COPY, COPY, CDXC, CDXC, LLEN, LLEN, LPH, LPHRedChip Companies to host a conference
15th Annual Small-Cap Conference is being held in San Francisco on October 15 with webcasted company presentations to begin at 11:30 am. Webcast Link
News For LPH;LLEN;CDXC;COPY;TAS;AEMD;LLTC;GALE;ASUR;NVTL;LQMT;NBS;LTBR;DKAM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
November 18, 2014
09:06 EDTCDXCChromaDex initiated with a Buy at Sidoti
Subscribe for More Information
07:37 EDTGALEStifel to hold a conference
Subscribe for More Information
07:20 EDTNBSNeoStem volatility elevated into presenting data
Subscribe for More Information
07:09 EDTGALEGalena completes enrollment in GALE-401 Phase 2 clinical trial
Galena Biopharma announced the completion of enrollment in the GALE-401, or Anagrelide Controlled Release, Phase 2 Clinical Trial. The Phase 2, clinical proof-of-concept study is treating 18 patients with elevated platelet counts in myeloproliferative neoplasms, or MPNs, including Essential Thrombocythemia, or ET, Polycythemia Vera, or PV, and Primary Myelofibrosis, or PMF. The Phase 2 trial is an open-label, single-arm, multicenter study designed to confirm the platelet-lowering activity of GALE-401 in patients with MPNs, to assess safety and tolerability, and to measure plasma concentrations of anagrelide. The platelet lowering ability of GALE-401 will be measured by the proportion of patients that achieve a complete or partial platelet response for at least four weeks during 24 weeks of treatment. With enrollment complete, patients will now be followed for platelet response while they continue study treatment.
07:09 EDTNBSNeoStem to host conference call
Subscribe for More Information
November 17, 2014
18:32 EDTNBSOn The Fly: After Hours Movers
Subscribe for More Information
17:18 EDTNBSNeoStem announces initial positive data from Phase 2 PreSERVE AMI clinical trial
NeoStem announced initial positive data from its 161 patient Phase 2 PreSERVE AMI,or acute myocardial infarction, clinical trial. These data are based on all enrolled patients being treated and having received six month follow-up for imaging and twelve month median length follow up for mortality, adverse events, serious adverse events, SAEs, and major adverse cardiac events, MACE."For cardiologists, our key goal is to keep patients from progressing to worsening heart muscle function and death after a major heart attack," said Dr. Arshed A. Quyyumi, Professor of Medicine at Emory University and Lead Principal Investigator of the PreSERVE AMI study. "It is encouraging to see clinically meaningful results this early in the study, and I look forward to future data readouts."
11:11 EDTNBSHigh option volume stocks:
Subscribe for More Information
November 14, 2014
15:34 EDTAEMDAethlon Medical device used to cure German Ebola patient, Fox reports
Subscribe for More Information
10:00 EDTNBSOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: AbbVie (ABBV) initiated with a Buy at Deutsche Bank... Advance Auto Parts (AAP) initiated with a Buy at Sterne Agee... AutoZone (AZO) initiated with an Underperform at Sterne Agee... Carter's (CRI) initiated with a Buy at Sterne Agee... Children's Place (PLCE) initiated with a Neutral at Sterne Agee... Container Store (TCS) initiated with a Fair Value at CRT Capital... DHT Holdings (DHT) initiated with a Buy at UBS... Diana Shipping (DSX) initiated with a Neutral at UBS... Genuine Parts (GPC) initiated with a Neutral at Sterne Agee... National Oilwell (NOV) initiated with a Neutral at UBS... Navios Acquisition (NNA) initiated with a Buy at UBS... NeoStem (NBS) assumed with a Buy at Maxim... O'Reilly Automotive (ORLY) initiated with a Neutral at Sterne Agee... Scorpio Bulkers (SALT) initiated with a Neutral at UBS... Star Bulk Carriers (SBLK) initiated with a Neutral at UBS... Teekay Tankers (TNK) initiated with a Buy at UBS... The Buckle (BKE) initiated with an Underweight at BB&T... TriMas (TRS) initiated with an Overweight at JPMorgan... TriplePoint Venture (TPVG) initiated with a Buy at UBS... Tsakos Energy (TNP) initiated with a Buy at UBS... USD Partners (USDP) initiated with an Outperform at Credit Suisse... Zumiez (ZUMZ) initiated with a Buy at BB&T.
09:07 EDTNBSNeoStem assumed with a Buy at Maxim
Subscribe for More Information
November 12, 2014
09:03 EDTLTBRLightbridge raises $5.04M in a registered direct offering
Subscribe for More Information
08:53 EDTASURAsure Software sees FY14 EPS ex-items 12c-16c, one estimate 14c
Subscribe for More Information
08:52 EDTASURAsure Software reports Q3 EPS 4c, one estimate 4c
Subscribe for More Information
08:12 EDTAEMDSeeThruEquity to hold a conference
Subscribe for More Information
November 11, 2014
09:17 EDTGALEOn The Fly: Pre-market Movers
UP AFTER EARNINGS: FMSA Holdings (FMSA), up 4.7% following third quarter results. ALSO HIGHER: AVEO Pharmaceuticals (AVEO), up 7.6% after entering agreement with Ophthotech (OPHT) to license tivozanib... Ophthotech is 2.1% higher in pre-market trading... Galena Biopharma (GALE), up 3.6% after first patient dosed in NeuVax and Herceptin combination Phase 2 trial... Yamana Gold (AUY), up 3% after being upgraded to Overweight from Neutral at HSBC... Ambac Financial (AMBC), up 3.1% after being upgraded to Neutral from Sell at MKM Partners... China Finance (JRJC), up 12.4% after announcing a new partnership with Great Wall Securities... Zynga (ZNGA), up 5.7% after being upgraded on mobile business growth at Jefferies... Fiat Chrysler (FCAU), up 2.2% after being initiated with a Conviction Buy at Goldman. DOWN AFTER EARNINGS: Applied Optoelectronics (AAOI), down 10.7%... Ekso Bionics (EKSO), down 2.2%. ALSO LOWER: Alibaba Group (BABA), down 1.6% following comments made by vice chairman Joseph Tsai in an interview.
07:06 EDTGALEGalena doses first patient in NeuVax, Herceptin combination Phase 2 trial
Subscribe for More Information
November 10, 2014
15:54 EDTAEMDAmerican Society of Nephrology to hold a conference
Subscribe for More Information
13:18 EDTGALEGalena terminates Brian Hamilton as Chief Medical Officer
Subscribe for More Information
November 7, 2014
07:14 EDTGALEGalena presents GALE-301 Phase 1/2a clinical trial data
Galena Biopharma announced that data from the company's Phase 1/2a trial of GALE-301, a Folate Binding Protein, or FBP,-derived immunotherapy, will be presented at the upcoming Society for Immunotherapy of Cancer Annual Meeting. Preliminary data shows a 31% recurrence rate in the vaccine group compared to 50% in the control group at a median follow up of 13 months, a 38% reduction in relative risk of recurrence. GALE-301 plus GM-CSF is well tolerated and elicits a strong in vivo immune response with primarily Grade 1 and Grade 2 toxicities. Top-line data to be presented mid-year 2015.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use